Dexfenfluramine
From Wikipedia, the free encyclopedia
 |
|
|
Dexfenfluramine
|
|
| Systematic (IUPAC) name | |
| N-Ethyl-1-[3-(trifluoromethyl)phenyl]-propan-2-amine | |
| Identifiers | |
| CAS number | |
| ATC code | A08 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H16F3N |
| Mol. mass | 231.257 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 36% |
| Metabolism | ? |
| Half life | 17-20 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Dexfenfluramine, also marketed under the name Redux, is an anorectic drug. It was for some years in the mid-1990s approved by the United States Food and Drug Administration for the purposes of weight loss. However, following multiple concerns about the side-effects of the drug, such approval was withdrawn.
The drug was manufactured by Interneuron Pharmaceuticals and marketed by Wyeth-Ayerst Laboratories. It is the enantiomer of fenfluramine.
[edit] See also
[edit] References
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
